Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read moreTZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read morePharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read moreChicago Headquartered Tempus, pioneering AI-enabled precision medicine, has entered a third strategic collaboration with pharma giant Pfizer, aiming to gather
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb announced on Friday that the European Commission (EC) has awarded the company with
Read moreIlinois-based pharmaceutical company Akorn Operating Co., is under investigation by the Illinois Department of Labor (IDOL), following the company’s filing
Read moreTransCode Therapeutics and BRAIN Biotech have entered a joint research and development agreement (JDA) with the objective to co-develop a
Read moreStemBioSys, Inc. (StemBioSys) announced on Monday, the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that is developed to enable the
Read moreThe European Union has authorized AstraZeneca’s Forxiga (dapagliflozin) to expand the treatment for heart failure (HF) with reduced ejection fraction
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreThe U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use
Read more